Is Mobosetinib produced in Japan?

Mobocertinib, discovered by Ariad Pharmaceuticals and developed by Takeda Pharmaceuticals (Takeda, Japan), is an irreversible tyrosine kinase inhibitor (TKI) that forms a covalent bond with cysteine 797 of EGFR, resulting in the inhibition of EGFR signaling and preventing EGFR exon 20 insertion mutations. It was approved by the U.S. Food and Drug Administration (FDA) in September 2021 for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

This is the first approval of oral targeted therapy for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Mobosetinib's route of administration, safety, objective response rate (ORR) and durable response offer significant advantages over existing treatments for this disease. Mobosetinib is marketed under the tradename Exkivity in capsule form and contains mobosetinibsuccinate as the active ingredient. These immediate-release capsules for oral administration contain 40mgmobosetinib without excipients.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.